Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
BioNTech
(NASDAQ:BNTX)
Intraday
$91.67
0
[0.00%]
After-Hours
$91.67
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$91.67
0
[0.00%]
At close: May 10
$91.67
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Mon May 6th, before the market open
The most recent conference call was at 8:00 AM, 7 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for BioNTech Stock (NASDAQ:BNTX)
BioNTech Stock (NASDAQ: BNTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, May 09, 2024
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Shanthi Rexaline
-
3 days ago
Wednesday, May 08, 2024
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $113
Benzinga Newsdesk
-
4 days ago
Tuesday, May 07, 2024
Cracking The Code: Understanding Analyst Reviews For BioNTech
Benzinga Insights
-
5 days ago
TD Cowen Maintains Hold on BioNTech, Raises Price Target to $98
Benzinga Newsdesk
-
5 days ago
BMO Capital Maintains Outperform on BioNTech, Lowers Price Target to $122
Benzinga Newsdesk
-
5 days ago
Monday, May 06, 2024
What's Going With BioNTech Stock On Monday?
Vandana Singh
-
6 days ago
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
-
6 days ago
Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young'
Shanthi Rexaline
-
6 days ago
BioNTech shares are trading lower following weaker-than-expected Q1 earnings.
Benzinga Newsdesk
-
6 days ago
BioNTech Reaffirms 2024 Revenue Guidance Of €2.5B-€3.1B
Benzinga Newsdesk
-
6 days ago
BioNTech Q1 2024 GAAP EPS €(1.31) Misses €(0.97) Estimate, Sales €187.600M Miss €427.500M Estimate
Benzinga Newsdesk
-
6 days ago
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Shanthi Rexaline
-
6 days ago
Wednesday, May 01, 2024
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Vandana Singh
-
May 1, 2024, 9:42AM
Friday, April 26, 2024
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Vandana Singh
-
Apr 26, 2024, 2:45PM
Thursday, April 25, 2024
Pfizer and BioNTech shares are trading lower amid reports GSK is suing the companies alleging patent infringement concerning mRNA technology used in their COVID-19 vaccines.
Benzinga Newsdesk
-
Apr 25, 2024, 3:34PM
What's Going On With Pfizer Stock On Thursday?
Vandana Singh
-
Apr 25, 2024, 1:51PM
Tuesday, April 23, 2024
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Vandana Singh
-
Apr 23, 2024, 3:00PM
Wednesday, April 17, 2024
Assessing BioNTech: Insights From 11 Financial Analysts
Benzinga Insights
-
Apr 17, 2024, 10:00AM
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $107 Price Target
Benzinga Newsdesk
-
Apr 17, 2024, 6:24AM
Friday, April 12, 2024
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Caleb Naysmith
-
Apr 12, 2024, 9:13AM
Monday, April 08, 2024
Reported Sunday, BioNTech Three-Year Phase 1 Follow-Up Data For mRNA-based Individualized Immunotherapy Candidate Shows Persistence Of Immune Response And Delayed Tumor Recurrence In Some Patients With Resected Pancreatic Cancer
Benzinga Newsdesk
-
Apr 8, 2024, 2:45AM
Thursday, April 04, 2024
CureVac, GSK Partner Release Data On Influenza Vaccine Study
Vandana Singh
-
Apr 4, 2024, 12:18PM
Wednesday, March 27, 2024
UBS Maintains Neutral on BioNTech, Lowers Price Target to $101
Benzinga Newsdesk
-
Mar 27, 2024, 2:14PM
Friday, March 22, 2024
JP Morgan Maintains Underweight on BioNTech, Lowers Price Target to $90
Benzinga Newsdesk
-
Mar 22, 2024, 12:37PM
Thursday, March 21, 2024
BMO Capital Maintains Outperform on BioNTech, Lowers Price Target to $123
Benzinga Newsdesk
-
Mar 21, 2024, 1:21PM
Cracking The Code: Understanding Analyst Reviews For BioNTech
Benzinga Insights
-
Mar 21, 2024, 12:01PM
Canaccord Genuity Reiterates Buy on BioNTech, Maintains $171 Price Target
Benzinga Newsdesk
-
Mar 21, 2024, 11:33AM
Wednesday, March 20, 2024
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Mar 20, 2024, 2:03PM
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
Upwallstreet
-
Mar 20, 2024, 1:38PM
Why Is BioNTech Stock Trading Lower On Wednesday?
Vandana Singh
-
Mar 20, 2024, 8:43AM
US Stock Futures Stall As Traders Await Fed Chair Powell's Decision; Analyst Sees S&P 500 Showing 'Signs Of Near-Term Top'
Shanthi Rexaline
-
Mar 20, 2024, 7:28AM
BioNTech shares are trading lower after the company reported worse than expected Q4 FY23 earnings and issued FY2024 guidance.
Benzinga Newsdesk
-
Mar 20, 2024, 6:24AM
BioNTech Expects FY2024 Sales Of €2.5B-€3.1B, With R&D Expenses Of €2.4B-€2.6B, SG&A Expenses Of €700M-€800M And Capital Expenditure Of €400M-€500M
Benzinga Newsdesk
-
Mar 20, 2024, 6:20AM
BioNTech Delivered Over 400M Covid-19 Vaccine Doses Worldwide In 2023, Including XBB.1.5 Variant-Adapted Monovalent Covid-19 Vaccine
Benzinga Newsdesk
-
Mar 20, 2024, 6:17AM
BioNTech Q4 GAAP EPS $2.04 Misses $2.64 Estimate, Sales $1.59B Miss $1.99B Estimate
Benzinga Newsdesk
-
Mar 20, 2024, 6:16AM
Earnings Scheduled For March 20, 2024
Benzinga Insights
-
Mar 20, 2024, 5:32AM
Tuesday, March 19, 2024
Earnings Outlook For BioNTech
Benzinga Insights
-
Mar 19, 2024, 10:01AM
Monday, March 11, 2024
BioNTech shares are trading higher after the company announced that it will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research Annual Meeting 2024.
Benzinga Newsdesk
-
Mar 11, 2024, 10:31AM
BioNTech To Present Clinical Data Updates for Personalized mRNA-Based And Targeted Oncology Candidates At AACR 2024
Benzinga Newsdesk
-
Mar 11, 2024, 7:53AM
Monday, March 04, 2024
5 Value Stocks In The Healthcare Sector
Benzinga Insights
-
Mar 4, 2024, 9:44AM
Wednesday, February 28, 2024
Goldman Sachs Maintains Neutral on BioNTech, Lowers Price Target to $100
Benzinga Newsdesk
-
Feb 28, 2024, 11:23AM
Friday, February 23, 2024
Canaccord Genuity Reiterates Buy on BioNTech, Maintains $171 Price Target
Benzinga Newsdesk
-
Feb 23, 2024, 10:13AM
Wednesday, February 21, 2024
Canaccord Genuity Reiterates Buy on BioNTech, Maintains $171 Price Target
Benzinga Newsdesk
-
Feb 21, 2024, 9:21AM
Tuesday, February 20, 2024
Cracking The Code: Understanding Analyst Reviews For BioNTech
Benzinga Insights
-
Feb 20, 2024, 2:00PM
Canaccord Genuity Maintains Buy on BioNTech, Raises Price Target to $171
Benzinga Newsdesk
-
Feb 20, 2024, 9:59AM
Monday, February 12, 2024
Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights
-
Feb 12, 2024, 9:43AM
Friday, February 09, 2024
MHRA Announced Approvals for Comirnaty (Pfizer/BioNTech), Nuvaxovid (Novavax) COVID-19 Vaccines
Charles Gross
-
Feb 9, 2024, 6:55AM
Thursday, February 08, 2024
BioNTech, Autolus Announce Strategic CAR-T Cell Therapy Collaboration And BioNTech Will Pay $50M million, Additionally BioNTech Agrees To Invest $200M In Autolus
Benzinga Newsdesk
-
Feb 8, 2024, 5:47AM
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Benzinga Newsdesk
-
Feb 8, 2024, 5:46AM
Friday, February 02, 2024
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
Vandana Singh
-
Feb 2, 2024, 2:01PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch